Catherine Wood, founder and CEO of ARK Invest, believes genomics – mapping the DNA building blocks of human life – is going to completely change the health-care landscape.
"Genomics is bringing technology into health care in such a way that we're seeing deflation — price deflation," said Wood, who owns a company called Illumina. That firm has a 90 percent share of all of the base pairs of DNA sequenced in the world, and their prices are falling 40 percent a year.
Companies such as testing firm Foundation Medicine are able to leverage off of that, she said. Illumina develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function. Foundation Medicine develops, manufactures and sells genomic analysis diagnostics for solid and circulating cancers.